SHPG has proven to be quite adept at striking deals that generate solid long-term returns for shareholders, and demonstrated excellent negotiating skills, as evidenced in the large breakup fee they received when ABBV pulled out of the deal to acquire SHPG last year. Whatever happens this time around I have little doubt this company will prosper.
What is increasingly certain is that the status quo is not an option. SHPG will either be acquired or will buy another company. I added a few shares today on this pullback.
Looks like SHPG found a takeover target, and it's a big fat one.
@@LONDON (Reuters) - Pharmaceutical company Shire (SHP.L) is considering a 12 billion pound ($18.32 billion) takeover of Actelion Ltd (ATLN.VX) Europe's biggest biotech firm, Britain's Sunday Times newspaper reported, citing unnamed sources. An informal approach by Shire was rebuffed several weeks ago, the newspaper said, citing financial industry sources. Shire was willing to pay 160 Swiss francs a share for Actelion, the sources said, a hefty premium to the stock's Friday closing price of 132 francs. Earlier this year, Actelion raised its full-year guidance after strong sales of its new heart and lung drug helped its first-quarter earnings exceed analysts' estimates.
something clearly leaked ... SHPG is considering a 12 billion pound ($18.32 billion) takeover of Actelion Ltd (ATLN.VX) Europe's biggest biotech firm, Britain's Sunday Times newspaper reported, citing unnamed sources. Lets see what transpires this upcoming week
Another raise by Deutsche bank. They really like this company. Shire is trading at 5635p on the LSE.
@@@@Shire : *DEUTSCHE BANK RAISES SHIRE PRICE TARGET TO 6000 PENCE - 'BUY' 05/27/2015 | 03:14am US/Eastern
In fact, PFE may just decide to go after SHPG. Boy won't that be fun!
@@@As speculation about a deal mounts again, analysts this week began picking their top takeover candidates. They centered on GlaxoSmithKline Plc, AstraZeneca and Shire Plc. And if you ask Mylan NV, it’s also on the list. The executive chairman was said to have told shareholders last week that Pfizer could buy his company after Mylan buys Perrigo Co. Any one of those deals may enable Pfizer to move its legal address to a place such as the U.K., where corporations have a lower tax burden. Some of its rivals have already done this and it’s led to a greater ability to access their overseas cash stockpiles and eke out more profits for future investments or shareholder payouts.
Really? Cause the rumour du jour I see is that PFE may be looking to buy GSK
@@@Pfizer Inc. would benefit from a takeover of U.K. rival GlaxoSmithKline Plc, a Deutsche Bank AG analyst wrote in a note to clients titled “Introducing PfizerKline.” A Glaxo acquisition would be “materially accretive” to earnings, Gregg Gilbert, a Deutsche Bank analyst based in New York, wrote in the note on Wednesday. Such a transaction would also allow Pfizer to “unlock access to its balance sheet and improve its tax situation,” he said. Pfizer hasn’t announced a takeover bid for London-based Glaxo, or indicated an interest.
This hedge fund does not seem concerned with the patent trolling by Bass and co.
@For three consecutive quarters, Shire SHPG has occupied the first spot in Paulson’s portfolio in terms of market value. His 8,328,304 shares are worth almost $2 billion and account for more than 10 percent of his total equity portfolio. The position remained unchanged over the first quarter.
And another one. Shire is currently trading at 5270 pence today on the LSE. Big boys all saying buy SHPG (SHP). Meanwhile K.Bass gets repeated opportunities to grow his short position.Stay tuned for the USPO to issue their decision sometime late summer on whether the petition will be allowed to proceed.
@@Shire : *MORGAN STANLEY RAISES SHIRE PRICE TARGET TO 6000 PENCE - 'OVERWEIGHT'
05/13/2015 | 03:46am US/Eastern
abbvie really are idiots not to have gone through with the shire deal. instead they pay 21 bill for half of ibrutinib.....oh well went well for dip buyers like mois